Gilead Sciences (GILD) Announces FDA Approval for Biktarvy for Treatment of HIV-1 Infection
February 7, 2018 2:24 PM
Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Biktarvy® (bictegravir 50mg/emtricitabine ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
